The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends

Received 6 January 2006; accepted 9 January 2006.

Abstract

The safety of blood transfusion is still threatened by contamination of blood products with a variety of pathogens such as viruses, bacteria and parasites. A novel pathogen reduction process for platelets and plasma products, the Mirasol PRT system, has been developed and is under clinical evaluation for its efficacy and safety. The Mirasol PRT process is based on riboflavin photochemistry. This manuscript reviews current progress and future trends.

Keywords: Riboflavin, Pathogen inactivation, Blood safety, Transfusion medicine

a Navigant Biotechnologies, Inc., 1215 Quail Street, Lakewood, CO 80215, United States

b Blood Components Technology and Haemostasis/Thrombosis Consultancy, 50 Primrose Hill Road, London NW3 3AA, United Kingdom

Corresponding author. Tel.: +1 303 250 2680; fax: +1 303 239 2389.

PII: S1473-0502(06)00085-1

doi:10.1016/j.transci.2006.01.007

4 of 12